Insecticides India Ltd

- Rajesh Aggarwal mentioned positive signs in exports and expects good orders in the current quarter. - Export turnover target for FY '24 is toned down to INR150 crores from INR200 crores earlier. - Orders expected in Q3 (September onwards), though these may not convert into sales in July or August. - The company is hopeful to cross the INR150 crores export turnover this year. - Focus on launching 4 new products in Q2, which will add to order pipeline. - Strong demand and all-time high sales in July indicate a robust order inflow in domestic markets as well.

- No explicit mention of fundraising through debt or equity in the provided transcript. - The company has spent around INR25 crores on land acquisition and plans a total capex of about INR150 crores over the next 2 years for expansion (Dahej, Sotanala, SEZ plant). - The majority of the capital expenditures appear to be funded internally or from ongoing operations, as there is no specific reference to raising funds externally. - Emphasis is on organic growth powered by R&D, registrations, capacity expansions, and product launches, targeting 20% CAGR in revenue over next 5 years. - No indications of plans for raising fresh equity or taking on new debt were discussed in the call excerpts.

- Chopanki technical plant capacity increased by ~50%; already in production. - Dahej plant to commence production post-Diwali 2023; 95% of expenses done. - Acquired ~15 acres land at Sotanala, Rajasthan (Sotanala District, Behror); INR 25 crores spent on acquisition. - Planned capex of approx. INR 100 crores over 2 years at Sotanala for formulation, technical synthesis, and possibly biological plant. - INR 25 crores planned for SEZ facility expansion (focused on export demand). - Another INR 25 crores allocated for routine expansions at Dahej and smaller projects including biologicals. - Total planned spend over next 2 years approximately INR 150 crores. - Biological plant location decision pending (Chopanki or Sotanala). - Focus on new product launches (7–8 products planned for FY '24–'25). - Upgraded technology systems: SAP HANA, BI dashboards, CRM with Salesforce for improved customer connectivity and risk mitigation.

- Targeting ~20% CAGR revenue growth over the next 5 years (Rajesh Aggarwal, Page 12 and 13). - FY 2024 revenue growth expected around 10% to 12%, with Q2 anticipated to be strong (Page 13). - Export turnover target initially INR 200 crores, revised to INR 150 crores for FY 2024, with better export numbers expected from September onward (Page 16 and 17). - Doubling of company turnover approximately every 5 years, from INR 500 crores in 2012 to near INR 2,000 crores currently (Page 17). - Focus on new product launches (4 lined up in Q2), value-added and patented products driving growth (Page 6, 14). - Biological products segment poised for meaningful launches starting FY 23-24, expected to contribute incremental revenue (Page 15). - Expansion capex of INR 150 crores planned to support capacity for anticipated growth (Page 12).

- The company targets a revenue CAGR of around 20% over the next 5 years. - EBITDA margin improvement is anticipated from current ~6% to 9-10% in FY24, with a longer-term goal of sustainable 12-13% margins. - Margin expansion is expected through R&D investments focused on new-generation and value-added patented molecules, and biological products. - Export turnover target for FY24 is revised to INR150 crores, with expectations to cross this from September onwards. - A capex of INR150 crores planned over the next 2 years to expand formulation and technical synthesis capacities, supporting growth. - Q2 is expected to be the strongest quarter with significant contributions from new product launches. - The company aims to improve operating profitability as high-cost inventory is liquidated and product mix shifts towards value-added products. - Conservative guidance for FY24 EBITDA margins is 9-10%, with optimism for double-digit margins in quarters going forward.